Kalaris Q1 net loss $10.9M; cash $104.9M; Phase 1b/2 TH103 screening patients

Kalaris Therapeutics, Inc.

2026-Q1 EPS reported -$0.46

Net loss $10.9M in Q1 2026 vs $10.2M in Q1 2025; R&D expense $7.6M (+27% YoY).
Cash and securities $104.9M at March 31, 2026, down from $118.0M at December 31, 2025; runway into Q4 2027.
Patient screening underway in Phase 1b/2 multiple-ascending-dose trial of TH103 for wet AMD; data expected 1H 2027.
New manufacturing batch completed with process enhancements reducing impurities; Phase 3 initiation on track for end of 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kalaris Therapeutics, Inc. reported financial results for quarter ended March 31, 2026.

Period: quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Research and Development Expenses : Research and development expenses were $7.6 million for the quarter ended March 31, 2026, compared with $6.0 million for the quarter ended March 31, 2025.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kalaris Therapeutics, Inc. reported financial results for quarter ended March 31, 2026.

Period: quarter ended March 31, 2026
Result: reported results

Exact text from the filing

General and Administrative Expenses : General and administrative expenses were $4.3 million for the quarter ended March 31, 2026, compared with $4.3 million for the quarter ended March 31, 2025.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-218240

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.